Cardiovascular disease is still the world’s number-one killer, and it’s substantially preventable. If you only ever learn one lab value, make it this one.
Particles, not cholesterol
Atherosclerosis isn’t caused by cholesterol per se — it’s caused by lipoprotein particles crossing the artery wall and getting stuck. Every one of those particles carries exactly one molecule of apolipoprotein B. Measure ApoB and you have counted the particles.
Standard panels report LDL-C: the cholesterol cargo, not the particle count. The two usually move together — but they diverge in exactly the people modern life produces most: insulin resistance, high triglycerides, small dense particles. Those patients can show a reassuring LDL-C while carrying a high particle burden. ApoB catches what LDL-C misses.
What the evidence says
- Head-to-head, ApoB predicts events better than LDL-C or non-HDL-C in meta-analyses of hundreds of thousands of patients.
- Mendelian randomization shows risk tracks lifetime exposure: particles × years. Starting earlier matters more than starting aggressively later.
- ApoB is a routine, inexpensive, standardized blood test. There is no practical reason not to know it.
Every LUMA baseline includes ApoB, Lp(a) once, and hs-CRP. Targets are individual — family history, Lp(a), and metabolic health move them — but the logic is constant: know your particle count, start lowering it early, verify on re-test.
How to move it
Order of operations: reduce refined carbohydrate and excess energy, replace saturated fat with unsaturated, add fiber (viscous fiber binds bile acids), train, sleep. When lifestyle plateaus and risk warrants it, modern lipid-lowering therapy is effective and well tolerated — a clinician conversation, made with a decade-long view.
Key references: Sniderman et al., JAMA Cardiology 2019 (ApoB superiority meta-analysis); Mendelian randomization studies of lifetime LDL exposure; AHA/ACC risk guidelines. Concept brand — not medical advice.
